Description
| - In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. I [R = CF3, (un)substituted-alkyl, -heteroaryl, -heteroarylalkyl, -cycloalkyl, -heterocyclyl, etc.; R1 = H, halo or alkyl; R2 = H, halo, CN, cycloalkyl, heterocyclyl, alkynyl and CF3; R3 = aryl (with exception of Ph), (un)subsituted-heteroaryl (with exception of furyl), -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by substitution of 8-chloro-6-methylimidzol[1,2-a]pyrazine with 3-(aminomethyl)pyridine. Methods for performing assays with I are described (no data).
- In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. I [R = CF3, (un)substituted-alkyl, -heteroaryl, -heteroarylalkyl, -cycloalkyl, -heterocyclyl, etc.; R1 = H, halo or alkyl; R2 = H, halo, CN, cycloalkyl, heterocyclyl, alkynyl and CF3; R3 = aryl (with exception of Ph), (un)subsituted-heteroaryl (with exception of furyl), -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by substitution of 8-chloro-6-methylimidzol[1,2-a]pyrazine with 3-(aminomethyl)pyridine. Methods for performing assays with I are described (no data). (en)
|